PT - JOURNAL ARTICLE AU - Poveda, Alaitz AU - Chen, Yan AU - Pomares-Millan, Hugo AU - Kurbasic, Azra AU - Patel, Chirag J AU - Renström, Frida AU - Hallmans, Göran AU - Johansson, Ingegerd AU - Franks, Paul W. TI - Environment-wide association study (EWAS) on cardiometabolic traits: A systematic assessment of the association of lifestyle variables on a longitudinal setting AID - 10.1101/2021.03.22.21254099 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.22.21254099 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254099.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254099.full AB - The present study aims to assess the over-time association of ∼300 lifestyle exposures with nine cardiometabolic traits with the ultimate aim of identifying exposures/exposure groups that could inform lifestyle interventions aiming at controlling cardiometabolic diseases. The analyses were undertaken in a longitudinal sample comprising >31000 adults living in northern Sweden. Linear mixed models were used to assess the average associations of lifestyle exposures and linear regression models were used to test association with 10-year change of the cardiometabolic traits. ‘Physical activity’ and ‘General Health’ were the exposure categories containing the highest number of ‘tentative signals’ in analyses assessing the average association of lifestyle variables, while ‘Tobacco use’ was the top-category for the 10-year change association analyses. Thirteen modifiable variables showed a consistent average association among the majority of cardiometabolic traits. These variables belonged to four main groups: i) Smoking, ii) Diet (secoisolariciresinol intake and brewed coffee), iii) Leisure time physical activity and iv) a group of variables more specific to the Swedish lifestyle (snuff status, hunting/fishing during leisure time and boiled coffee). Interestingly, sweet drinks, fish intake and salt content, all lifestyle exposures frequently mentioned in public health recommendations were not broadly associated with the analysed cardiometabolic traits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work described in this paper was supported by the Innovative Medicines Initiative of the European Union (no. 875534 SOPHIA), by the European Research Council (CoG-2015_681742_NASCENT), Swedish Research Council, Strategic Research Area Exodiab, (Dnr 2009-1039), the Swedish Foundation for Strategic Research (IRC15-0067), and the Swedish Research Council, Linnaeus Grant (Dnr 349-2006-237).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Ethical Review Board in UmeaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data generated and analyzed are not publicly available due to Swedish legislation but are available from the Department of Biobank Research, Umea University, on reasonable request and with appropriate approvals